The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.

Ni, Ying; Fang, Jian; Zhu, Linqi; Jiang, Hui; Liu, Yun; Miao, Renjie; Shao, Chen; Shao, Shihe

doi:10.7150/jca.25264

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased ZEB1-AS1 expression has been demonstrated to contribute to the upregulated expression of ZEB1, the progression to EMT and cancer metastasis (20). Furthermore it is also significantly associated with tumor progression and patient survival, in many different types of cancer (25). However, few studies have examined other mechanisms that involve the oncogenic role of ZEB1-AS1.…”

Section: Discussionmentioning

confidence: 99%

LncRNA ZEB1‑AS1 reduces liver cancer cell proliferation by targeting miR‑365a‑3p

Li¹,

Guan

Yu-ping

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

Liver carcinoma is one of the most common malignancies worldwide. Previous studies have demonstrated that long non-coding RNAs (lncRNAs) are crucial mediators that participate in a wide range of molecular processes associated with carcinogenesis. However, little is known about the specific mechanisms that underlie the majority of lncRNAs. Many studies have indicated that lncRNAs affect microRNA (miRNA or miR) activities via physical base-paired binding, therefore serving as competing endogenous RNAs (ceRNAs) that indirectly regulate the expression of miRNA targets. In the current study, it was revealed that lncRNA zinc-finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) serves as a ceRNA for miR-365a-3p, functioning to positively modulate E2F transcription factor 2 (E2F2) expression in liver cancer cells. Additionally, reverse transcription-quantitative polymerase chain reaction demonstrated that levels of ZEB1-AS1 were abnormally upregulated in liver cancer and this was positively correlated with E2F2 expression. Furthermore, high levels of ZEB1-AS1 exhibited a trend for poor survival in patients with liver cancer. Western blot analysis demonstrated that ZEB1-AS1 silencing could reduce E2F2 expression. EdU staining and flow cytometry analysis indicated that downregulation of ZEB1-AS1 could suppress cell proliferation and decrease the S phase proportion of liver cancer cells, which was effectively reversed by the inhibition of miR-365a-3p. ZEB1-AS1 was also determined to be physically associated with miR-365a-3p, while miR-365a-3p was revealed to target the E2F2 3′UTR for degradation or translational repression. The results also demonstrated that ZEB1-AS1 positively regulates E2F2 expression by competitively binding to miR-365a-3p. It was further revealed to enhance liver cancer cell proliferation. Thus, these results indicate that ZEB1-AS1 is required for liver cancer progression in a ceRNA dependent manner. ZEB1-AS1 may therefore be a potential target for liver cancer intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA ZEB1‑AS1 reduces liver cancer cell proliferation by targeting miR‑365a‑3p

Li¹,

Guan

Yu-ping

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…A variety of LncRNAs have the potential to act as biomarkers, Ni et al (2018) reported that ZEB1-AS1 resulting in shorter OS may be a useful biomarker for predicting a poor prognosis. Kim et al (2015) reported that HOTAIR is associated with human cervical cancer progression.…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA Breast cancer antiestrogen resistance 4 is associated with cancer progression and its significant prognostic value

Zhao

Wang

Xiao

et al. 2018

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

Breast cancer antiestrogen resistance 4 (BCAR4) is a novel long noncoding RNA. It was originally identified in a screen for genes responsible for the development of resistance to antiestrogens in breast cancer cells and plays a major role in various tumors. However, the clinical diagnostic role of BCAR4 in tumors is not completely understood. This current meta‐analysis aimed to comprehensively explore the potential role of BCAR4 as a prognostic biomarker in a number of cancers. Five public databases PubMed, EMBASE, Web of Science, Wiley Online Library, and Medline were used to search for articles. Nine studies comprising 1,293 patients were included in this meta‐analysis. The results of analysis showed that BCAR4 expression in human cancer was significantly associated with poor overall survival (hazard ratio [HR] = 1.98, confidence interval [CI]: [1.71–2.29]), p < 0.00001, and high BCAR4 expression was associated with clinical stage (OR and its 95% CI was 3.30 [1.99–5.46], p < 0.00001), distant metastasis (OR = 3.83, 95% CI: 2.15–6.82, p < 0.00001), and lymph node metastasis (OR and its 95% CI was 2.91 [1.62–5.25], p = 0.0004) in patients with cancer. Furthermore, the results revealed the prognostic significance of BCAR4 in gastrointestinal malignancy, breast cancer, and osteosarcoma (HR and its 95% CI were 2.05 [1.56–2.68], p < 0.00001; 1.78 [1.46–2.16], p < 0.00001; and 2.47 [1.41–4.34], p < 0.00001, respectively). This meta‐analysis indicated the potential value of BCAR4 as a biomarker for predicting a poor prognosis in patients with cancer.

show abstract

“…Since then, ZEB1-AS1 has been demonstrated to be overexpressed in glioma (16), colorectal cancer (17), gastric cancer (18), prostate cancer (19) Long non-coding RNA ZEB1-AS1 predicts a poor prognosis and promotes cancer progression through the miR-200a/ZEB1 signaling pathway in intrahepatic cholangiocarcinoma and cervical cancer (20). ZEB1-AS1 mainly functions as an oncogene and promotes cancer progression (21). ZEB1-AS1 upregulation has been shown to be associated with a poor prognosis in multiple types of cancer (22).…”

Section: Introductionmentioning

confidence: 99%

Long non‑coding RNA ZEB1‑AS1 predicts a poor prognosis and promotes cancer progression through the miR‑200a/ZEB1 signaling pathway in intrahepatic cholangiocarcinoma

et al. 2020

View full text Add to dashboard Cite

Emerging evidence suggests that long non-coding RNAs (lncRNAs) play pivotal roles in cancer progression, including in intrahepatic cholangiocarcinoma (IHCC). The overexpression of lncRNA ZEB1 antisense 1 (ZEB1-AS1) has been discovered in several types of cancer; however, the clinical significance and functional role of ZEB1-AS1 in IHCC have not yet been determined. In the present study, ZEB1-AS1 was found to be upregulated in IHCC cell lines and tissues. A high ZEB1-AS1 expression was associated with clinical progression and a poor survival of patients with IHCC, and was identified as an independent risk factor for a poor prognosis. In addition, ZEB1-AS1 promoted the proliferation and metastasis of IHCC cells both in vitro and in vivo. ZEB1-AS1 was demonstrated to increase the expression of ZEB1 by sponging miR-200a and to thereby accelerate epithelial-mesenchymal transition (EMT). On the whole, the findings of the present study demonstrate that ZEB1-AS1 promotes proliferation and metastasis in IHCC, and induces EMT through the miR-200a/ZEB1 signaling pathway. ZEB1-AS1 may thus be a promising prognostic biomarker and essential therapeutic target for IHCC.

show abstract

The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.

Cited by 3 publications

References 20 publications

LncRNA ZEB1‑AS1 reduces liver cancer cell proliferation by targeting miR‑365a‑3p

LncRNA ZEB1‑AS1 reduces liver cancer cell proliferation by targeting miR‑365a‑3p

Long noncoding RNA Breast cancer antiestrogen resistance 4 is associated with cancer progression and its significant prognostic value

Long non‑coding RNA ZEB1‑AS1 predicts a poor prognosis and promotes cancer progression through the miR‑200a/ZEB1 signaling pathway in intrahepatic cholangiocarcinoma

Contact Info

Product

Resources

About